1. Home
  2. Nation
  3. Hester Biosciences in talks with Bharat Biotech for tech transfer of ‘Covaxin’

Hester Biosciences in talks with Bharat Biotech for tech transfer of ‘Covaxin’

By Saima Siddiqui 
Updated Date
Hester Biosciences in talks with Bharat Biotech for tech transfer of ‘Covaxin’

New Delhi: Hester Biosciences is reportedly in discussions with Bharat Biotech for technology transfer to produce ‘Covaxin’ is underway. Ahmedabad-based Hester is into animal and poultry vaccines.

Also Read :- With 41,649 fresh cases India's daily Covid tally rises for 4th consecutive day

“A triparty consortium has been formed with the Government of Gujarat as the lead partner, to explore the prospects of manufacturing the Covid vaccine through technology from Bharat Biotech,” Hester said in a statement.

“The discussions are currently on-going with Bharat Biotech towards reviewing the infrastructure at Hester, the technology adoption process and the regulatory compliance. Based on the outcome of the review, the next course of action will be determined,” the statement added.

Notably, Gujarat Biotechnology Research Centre, Hester Biosciences, and OmniBRx Biotechnologies firmed up discussions with Bharat Biotech which would help them produce an additional 20 million doses per month.

Bharat Biotech has already signed agreements with three public sector undertakings such as Hyderabad-based Indian Immunologicals Ltd, Mumbai-based Haffkine Biopharmaceuticals, and Bharat Immunologicals and Biologicals Limited (BIBCOL), a DBT facility at Bulandshahr in Uttar Pradesh.

Also Read :- Rahul Gandhi gets first Covid-19 vax jab, misses Parliament session

Bharat Biotech has stated that it will be adding 700 million doses per annum of ‘Covaxin’ capacity by the end of 2021.

Further reading:
For the latest news and reviews, follow us on Facebook and Twitter ...
X